{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01090817",
      "OrgStudyIdInfo": {
        "OrgStudyId": "EC2009/123"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "CTN2010/0098",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Therapeutics Good Administration, Government of Australia"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Royal Perth Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease",
      "OfficialTitle": "A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2015",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2015",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "March 22, 2010",
      "StudyFirstSubmitQCDate": "March 22, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 23, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 7, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 9, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "R.P.Herrmann",
        "ResponsiblePartyInvestigatorTitle": "Director Cell and Tissue Therapies Western Australia",
        "ResponsiblePartyInvestigatorAffiliation": "Royal Perth Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "R.P.Herrmann",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "The Queen Elizabeth Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Concord Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Sir Charles Gairdner Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "The Alfred",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery. The hypothesis is that mesenchymal stromal cell therapy using third party human cultured cells will be safe and effective"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Crohn Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "mesenchymal stromal cells",
          "ileitis",
          "colitis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "21",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stromal cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Mesenchymal stromal cells administered weekly for 4 weeks",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal stromal cells (MSC) for infusion"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal stromal cells (MSC) for infusion",
            "InterventionDescription": "MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stromal cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "No other names"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy",
            "PrimaryOutcomeDescription": "Colonoscopy and biopsy as well as clinical parameters used for the Crohn's disease acivity (www.ibdaustralia.org/cdai/) will be undertaken at screening pre-therapy and at 6 weeks after start of therapy.",
            "PrimaryOutcomeTimeFrame": "Six weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Incidence of infusional toxicity",
            "SecondaryOutcomeDescription": "Subjects will receive mesenchymal stromal cell therapy, 2X10E6/kg weekly by IV infusion for 4 weeks and will be assessed for 4 hours post infusion",
            "SecondaryOutcomeTimeFrame": "Six weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Induction of remission",
            "SecondaryOutcomeDescription": "Crohn's disease activity index assessed as below 150",
            "SecondaryOutcomeTimeFrame": "Six weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improved quality of life",
            "SecondaryOutcomeDescription": "Increase in IBDQ and SF-36 scores measured at six weeks",
            "SecondaryOutcomeTimeFrame": "Six weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Endoscopic improvement.",
            "SecondaryOutcomeDescription": "Crohn's disease endoscopic improvement score will be measured at repeat endoscopy six weeks after start of treatment",
            "SecondaryOutcomeTimeFrame": "Six weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nColonic or small bowel Crohn's disease based on endoscopic appearances and histology\nRefractory to induction with infliximab or adalimumab; or have lost response to these agents; or have had side effects precluding their further use\nWhere there has been loss of response to one of these agents, the other must be tried before being eligible\nCrohn's disease activity score (CDAI) 250 or more.\nC-reactive protein >10mg/L\nSurgery must have been offered to the subject (if appropriate) and declined\nSigned informed consent\n\nExclusion Criteria:\n\nActive sepsis, perforating disease. Coexistent perianal fistulous disease is permitted, providing no co-existent infection within previous 4 weeks\nChronic stricturing disease in isolation\nCoexistent CMV disease\nPrior history of malignancy\nPregnant or unwilling to practice contraceptive therapy or breast feeding females\nLast biologic therapy must be greater than 4 weeks prior, must be on stable corticosteroid dose for 14 days prior, during therapy and for 14 days after therapy, must be on stable immunomodulator dose (eg, azathioprine) for 14 days prior, during therapy and for 14 days after.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "55 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Geoff Forbes, MD",
            "OverallOfficialAffiliation": "Royal Perth Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Gastroenterology and Hepatology, Royal Perth Hospital",
            "LocationCity": "Perth",
            "LocationState": "Western Australia",
            "LocationZip": "6000",
            "LocationCountry": "Australia"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23872668",
            "ReferenceType": "derived",
            "ReferenceCitation": "Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014 Jan;12(1):64-71. doi: 10.1016/j.cgh.2013.06.021. Epub 2013 Jul 19."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003424",
            "ConditionMeshTerm": "Crohn Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000015212",
            "ConditionAncestorTerm": "Inflammatory Bowel Diseases"
          },
          {
            "ConditionAncestorId": "D000005759",
            "ConditionAncestorTerm": "Gastroenteritis"
          },
          {
            "ConditionAncestorId": "D000005767",
            "ConditionAncestorTerm": "Gastrointestinal Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000007410",
            "ConditionAncestorTerm": "Intestinal Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M5790",
            "ConditionBrowseLeafName": "Crohn Disease",
            "ConditionBrowseLeafAsFound": "Crohn's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5472",
            "ConditionBrowseLeafName": "Colitis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9279",
            "ConditionBrowseLeafName": "Ileitis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9596",
            "ConditionBrowseLeafName": "Intestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17069",
            "ConditionBrowseLeafName": "Inflammatory Bowel Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8027",
            "ConditionBrowseLeafName": "Gastroenteritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}